Form 4: Integrated BioPharma CFO Acquires Stock Options
SEC Form 4
Integrated BioPharma's Chief Financial Officer, Dina Masi, was granted stock options for 125,000 shares on December 4, 2024.
Summary
- Dina Masi, the Chief Financial Officer of Integrated BioPharma Inc., was granted stock options to purchase 125,000 shares of the company's common stock.
- The options have an exercise price of $0.31 per share.
- The options vest in three equal annual installments, with the first vesting on December 4, 2025.
- The options expire on December 4, 2034.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.
Positives
- The granting of stock options to the CFO aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- If the stock price does not increase above the exercise price, the options will have no value.
Future Outlook
The stock options will vest over the next three years, incentivizing the CFO to contribute to the company's long-term success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of three years is also typical, encouraging long-term performance.
- The exercise price of $0.31 is specific to the company's current stock price and market conditions.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 12/04/2024 | Date of the stock option grant. |
| 12/04/2025 | Date of the first vesting installment. |
| 12/04/2034 | Expiration date of the stock options. |
| 12/05/2024 | Date the form was signed. |
Keywords
stock options, insider trading, executive compensation, Dina Masi, Integrated BioPharma, INBP, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.